Corden Pharma - A Full-Service CDMO

>16 July: CordenPharma Invests €900m in Transformational Peptide Platform Expansion. Read Press Release: https://lnkd.in/enqc-t8b We are pleased to announce a record investment of ~€900m over the next 3 years in expanding our peptide platform, both at our Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements. Our CordenPharma Colorado, US site expansion involves the planned construction of a new large-scale peptide manufacturing facility, and an additional increase in manufacturing trains in the existing facility. This is the result of rapidly increasing demand in the Diabetes and Obesity Glucagon-like Peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totaling ~€3bn, with potential upsides. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. These major expansion plans will act as the driving force behind our €1bn sales target for our Peptide Platform by 2028, reinforcing CordenPharma as a market leader in the integrated supply of small to large-scale services from APIs to Drug Products (for both Injectable and Oral Peptides). Dr. Michael Quirmbach, President & CEO of the CordenPharma Group comments: “These investments will profoundly strengthen our ability to provide valuable and much needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts.” Dr. Signe Michel, Managing Director at Astorg comments: “We are proud of what Michael and the CordenPharma team have achieved through their striving for operational excellence, customer service and ambitious growth. We are excited about the opportunities ahead and to further strengthen the company’s peptide offering across the full drug lifecycle and value chain.” Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the company’s proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity.” #CordenPharma #cdmo #peptides #GLP1s #diabetes #obesity #peptideagonists #oralpeptides #injectables #pharmamanufacturing #pharmaceuticals

Learn more about our LNP Manufacturing Services. Our new cGMP Lipid NanoParticle (LNP) manufacturing facility in Caponago, Italy, is FDA and EMA approved. Building on decades of sterile injectable experience, it fully supplements our existing LNP development capabilities. The 900 m² suite is state-of-the-art, Grade C throughout, fully scalable, and offers process and purification scale-up, including the following technologies and services: -A full variety of nanoparticle assembly systems, notably Impingement Jets Mixing (IJM) by Knauer and NxGen Microfluidic technology by Cytiva -A wide selection of purification technologies such as Ultrafiltration (UF), Diafiltration (DF) and Tangential Flow Filtration (TFF) - Comprehensive analytical services As part of our fully-integrated offering CordenPharma additionally offers Aseptic Fill & Finish services conveniently located under the same roof, as well as a wide selection of functional Lipid Excipients provided within the CordenPharma facility network. https://lnkd.in/d8EdQ_bf   #CordenPhama #CDMO #LNP #lipidnanoparticles #pharmaceuticals #pharma #pharmaindustry #injectables

The Q2/24 edition of our newsletter Corden Connect is out today! Learn more about our new cGMP Lipid NanoParticle (LNP) manufacturing facility in Italy, the important role of crystallization processes, and our end-to-end Tides CDMO services & growth strategy in an interview with S. VP Mimoun Ayoub. https://lnkd.in/dgeX2-af Want to receive our latest news directly in your inbox? Sign up for our newsletter https://lnkd.in/d3vNGMPX #cordenpharma #cdmo #drugdevelopment #pharma #pharmaceuticals #pharmaindustry #lipidsnanoparticles #crystallization

Discover our diverse and vibrant company culture and how we foster our core values, vision, and mission that drive our success! #CordenPharma #CDMO #WorkCulture #Teamwork #JoinUs #mission #vision

Dr. Mimoun Ayoub, Ph.D., Senior VP, Global Head of Sales & Key Account Management, discusses our broad CDMO capabilities to supply complex modalities such as small to large-scale peptides (including GLP-1s), lipids and oligos, as well as Lipid NanoParticle (LNP) formulation, sterile injectable drug products, and our extensive capacity of small molecule APIs & Drug Products, both highly potent and regular potency for Oral Solid Dosage. Learn more about our six technology platforms and how we support you in delivering complex modalities to your patients: https://lnkd.in/ejrr4frU #cordenpharma #cdmo #pharma #pharmaceuticals #drugdiscovery #drugdevelopment #pharmaceuticals #lipids #peptides #highlypotent #injectables #lnps

Want to learn more about the application of flow chemistry and PAT in crystallization process development within a CDMO environment? Join our scientific experts presenting posters at the BOSS XVIII symposium in Liège, Belgium, where we are proud to be Gold sponsor!   Today, come and discuss with Dr. Clemens Horn about the benefits of Flow Chemistry.  Tomorrow and Thursday, discuss with Dr. Tobias Wedel about the benefits of developing robust crystallization processes with the help of PAT.   #BOSS_Symposium #BOSSXVIII #flowchemistry #crystallisation #cdmo 

Summer Events Initiative: Giving Back to Our Community At CordenPharma we believe in the importance of giving back to the community and in the power of making a positive impact, not just in our industry but in the society as a whole. Our summer events are the perfect occasion to do this! We're very proud to support twelve healthcare organizations with donations towards diverse diseases, in many of our business focus areas. These contributions are a way for us to participate meaningfully, in alignment not only with our values but also with our purpose. We are part of a community that prioritizes empathy, teamwork, and progress. Stay tuned for updates on our journey and the difference we are making together. Thank you for your continued support and for being part of this initiative. Together, we can make a difference! #CommunitySupport #HealthcareInitiative #GivingBack #CorporateResponsibility #SummerEvent #MakingADifference

> CordenPharma hosts the 2024 Swiss Fine Chemical Association annual meeting at our Liestal, Switzerland site! The SFCA is a group of Swiss CDMOs that meet annually at rotating locations of the member companies. This year, it was CordenPharma’s turn to host the meeting at our Liestal, CH site, organized by Managing Director Thomas Müller. On 13 June, CordenPharma invited attendees to join for an aperitif and networking dinner. The next day, on 14 June, Thomas Mueller was joined by CEO Michael Quirmbach, Associate Director of Sales Steffen Bira, and former Liestal Managing Director and long-time colleague Juerg Burger to host ~2 representatives from each member CDMO. A full program of inspirational speeches was organized, followed by a lively exchange amongst member companies. Speakers and topics included: · Jade Sternberg of digitalswitzerland presented a talk on “The power of ecosystems to digitally transform a country – a perspective from Switzerland’s leading digital association.” · Felix Georg Mueller of plus10 presented a talk on “Intelligent efficiency increase in pharma production lines though GMP-compliant AI software tools.” · Francesco Crivelli of CSEM spoke on “AI for predictive analytics, in maintenance and quality control.” Thomas Mueller commented, “We had an engaging dinner and full program of interesting topics impacting the CDMO landscape. It was great to welcome member companies to this event to network, exchange ideas, and as we do every year, have discussions on trends. This year we organized very informative talks on the game-changing topics of digitalization and AI that not only affect the future of pharma in Switzerland, but globally as well. We look forward to future meetings at other SFCA member locations to come!”   #SFCA #swisschemicals #cdmo #pharmamanufacturing #pharmaceuticals #CordenPharma #digitalization #AI #predictiveanalytics #supplychain

Expanding our global reach with new Lipid & LNP Starter Kit stock in Tokyo, Japan! As we recognize the importance of access to the supply of effective pharmaceutical-grade lipids with reduced order-to-delivery times, we are excited to announce the establishment of a new lipid stock in Tokyo, Japan. This strategic move provides enhanced proximity to a specially selected group of our highly pure standard lipids, including those proven to be effective in our new Lipid NanoParticle (LNP) Starter Kits, to our valued Asian and Japanese customers.    For more information or to place an inquiry for our Japan stock of Lipids and LNP Starter Kits, click here: https://lnkd.in/ecByaKK7   #cordenpharma #cdmo #lipids #japan #lnps #lipidnanoparticles #pharmaceuticals #pharma #pharmaindustry #lnp #mrna #genetherapy 

> Press Release 19 June: WACKER & CordenPharma are pleased to announce their joint consortium has officially entered the pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in stand-by phase for at least five years. In the event of a new pandemic, WACKER and CordenPharma have taken the necessary steps to produce 80 million vaccine doses a year within an extremely short time, with most of the production steps taking place in Germany, and every production step occurring within the European Union. As part of the consortium, CordenPharma is ready to manufacture custom and standard lipids in our Frankfurt (DE) and Chenôve (FR) sites, as well as provide aseptic fill & finish and packaging of the chosen mRNA-based vaccine at our Caponago (IT) facility. In its site in Halle (Germany), WACKER will produce plasmid DNA (pDNA), which is an essential starting material for the manufacture of mRNA. Dr. Michael Quirmbach, CEO of CordenPharma Group, commented: “Obtaining the official confirmation of pandemic readiness by the German government is a major milestone for CordenPharma. I am extremely proud of our teams across the CordenPharma sites involved in establishing and delivering our pandemic readiness plan on schedule. We are now ready, together with our partner WACKER, to manufacture end-to-end mRNA-based vaccines for the German government and other customers.” “We have expanded our Halle site into a Competence Center for mRNA production,” said WACKER CEO Dr. Christian Hartel. “WACKER has invested over 100 million Euros in this expansion and created over 100 highly qualified jobs. Our expertise in making mRNA and LNPs will contribute to the fight against future pandemics. Together with CordenPharma, we are proud to serve the German government in its pandemic preparedness plans.” Read the full press release here: https://lnkd.in/d6vBdaPK #CordenPharma #wacker #pandemic #mrna #pdna #lipids #injectables #fillfinish #pharmaceuticals #vaccine #germany